Wall Street expects a year-over-year increase in earnings on higher revenues when SpringWorks Therapeutics (SWTX) reports results for the quarter ended December 2024. While this widely-known consensus ...

We recently compiled a list of the 10 Firms Begin Trading Week With Impressive Gains. In this article, we are going to take a ...

SpringWorks Therapeutics (SWTX) has announced that the U.S. Food and Drug Administration has approved Gomekli, a small molecule MEK inhibitor, ...

BofA raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $87 from $65 and keeps a Buy rating on the shares. Shares gained a ...

SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...

SpringWorks Therapeutics ( NASDAQ: SWTX) soared ~40% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions ...

Germany-based Merck KGaA (OTC:MKGAF) (OTC:MKKGY) reacted to press reports and confirmed advanced discussions with SpringWorks ...

SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a research report issued on Monday,RTT News reports.

Whales with a lot of money to spend have taken a noticeably bullish stance on SpringWorks Therapeutics. If we consider the ...

In this article, we are going to take a look at where SpringWorks Therapeutics Inc. (NASDAQ:SWTX) stands against the other stocks. The stock market kicked off the trading week on a positive note ...